Wu TC, Stube A, Felix C, Oseguera D, et al. Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2023 Apr 4:S0360-3016(23)00325.
PMID: 37023987